These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 12920387)
21. [4th International Symposium. "Cerebrolysin: pharmacological effects and role in clinical practice"]. Gomazkov OA Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):69-70. PubMed ID: 12378888 [No Abstract] [Full Text] [Related]
22. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study. Wong GK; Zhu XL; Poon WS Acta Neurochir Suppl; 2005; 95():59-60. PubMed ID: 16463821 [TBL] [Abstract][Full Text] [Related]
24. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Masliah E; Armasolo F; Veinbergs I; Mallory M; Samuel W Pharmacol Biochem Behav; 1999 Feb; 62(2):239-45. PubMed ID: 9972690 [TBL] [Abstract][Full Text] [Related]
25. Morphofunctional effects of moderate forebrain ischemia combined with short-term hypoxia in rats--protective effects of Cerebrolysin. Schwab M; Schaller R; Bauer R; Zwiener U Exp Toxicol Pathol; 1997 Feb; 49(1-2):29-37. PubMed ID: 9085071 [TBL] [Abstract][Full Text] [Related]
26. [Cerebrolysin treatment of mild cognitive impairment of vascular genesis]. Damulin IV; Mkhitarian EA; Koberskaia NN Ter Arkh; 2007; 79(6):65-9. PubMed ID: 17684971 [TBL] [Abstract][Full Text] [Related]
27. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Masliah E; Díez-Tejedor E Drugs Today (Barc); 2012 Apr; 48 Suppl A():3-24. PubMed ID: 22514792 [TBL] [Abstract][Full Text] [Related]
28. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin. Ruether E; Alvarez XA; Rainer M; Moessler H J Neural Transm Suppl; 2002; (62):265-75. PubMed ID: 12456069 [TBL] [Abstract][Full Text] [Related]
29. [Effect of the nootropic agent cerebrolysin in cerebral ischemia in rats with varying behavioral reactions in the open field test]. Gannushkina IV; Antelava AL; Baranchikova MV Patol Fiziol Eksp Ter; 1998; (2):3-8. PubMed ID: 9633187 [TBL] [Abstract][Full Text] [Related]
30. [Experience with using high doses of cerebrolysin in vascular dementia]. Iakhno NN; Damulin IV; Zakharov VV; Levin OS; Elkin MN Ter Arkh; 1996; 68(10):65-9. PubMed ID: 9026950 [TBL] [Abstract][Full Text] [Related]
31. [Efficacy of prolonged therapy of vascular dementia]. Klin Med (Mosk); 2011; 89(5):57-60. PubMed ID: 22242270 [TBL] [Abstract][Full Text] [Related]
32. Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin. Onose G; Mureşanu DF; Ciurea AV; Daia Chendreanu C; Mihaescu AS; Mardare DC; Andone I; Spânu A; Popescu C; Dumitrescu A; Popescu M; Grigorean V; Ungur B; Marinescu F; Colibbeanu I; Onose L; Haras M; Sandu A; Spircu T J Med Life; 2009; 2(4):350-60. PubMed ID: 20108748 [TBL] [Abstract][Full Text] [Related]
33. Accelerated recovery from acute brain injuries: clinical efficacy of neurotrophic treatment in stroke and traumatic brain injuries. Bornstein N; Poon WS Drugs Today (Barc); 2012 Apr; 48 Suppl A():43-61. PubMed ID: 22514794 [TBL] [Abstract][Full Text] [Related]
34. Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury. Zhang Y; Chopp M; Zhang ZG; Zhang Y; Zhang L; Lu M; Zhang T; Winter S; Doppler E; Brandstäetter H; Mahmood A; Xiong Y Neurorehabil Neural Repair; 2019 Jan; 33(1):15-26. PubMed ID: 30499355 [TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Poon W; Matula C; Vos PE; Muresanu DF; von Steinbüchel N; von Wild K; Hömberg V; Wang E; Lee TMC; Strilciuc S; Vester JC Neurol Sci; 2020 Feb; 41(2):281-293. PubMed ID: 31494820 [TBL] [Abstract][Full Text] [Related]
37. [Cerebrolysin in treatment of painful diabetic neuropathy]. Biesenbach G; Grafinger P; Eichbauer-Sturm G; Zazgornik J Wien Med Wochenschr; 1997; 147(3):63-6. PubMed ID: 9173675 [TBL] [Abstract][Full Text] [Related]
38. [The effect of cerebrolysin on moderate cognitive impairment in cerebral vascular insufficiency (a clinical and electrophysiological study)]. Damulin IV; Koberskaia NN; Mkhitarian EA Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(5):32-8. PubMed ID: 18379494 [TBL] [Abstract][Full Text] [Related]
39. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. Muresanu DF; Rainer M; Moessler H J Neural Transm Suppl; 2002; (62):277-85. PubMed ID: 12456070 [TBL] [Abstract][Full Text] [Related]
40. [Cerebrolysin in neurological and psychiatric practice]. Vilenskiĭ BS Lik Sprava; 1997; (6):139-42. PubMed ID: 9589960 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]